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Obesity is a currently a major problem plaguing the world as a whole. 1  The 
International Obese Task Force (IOTF) estimates at least 1.1 billon adults are overweight 
with some 312 million of those obese, globally. 1  As of 2004, in less than twenty years, the 
prevalence of obesity had more than doubled in adults with childhood obesity prevalence 
rising even more rapidly. 1  Obesity, however, can be classified as a disease of its own or as 
a symptom of another disease.  Two such diseases that have obesity as a symptom are 
Metabolic Syndrome and Cushing’s Syndrome. 2 , 3 , 4 , 5   
Metabolic Syndrome is a condition that is represented by the presence of multiple 
risk factors. These factors, as indicated by The National Cholesterol Education Program 
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults 
(Adult Treatment Panel III), include elevated waist circumference, elevated triglycerides, 
reduced high-density lipoprotein cholesterol (HDL-C), elevated blood pressure and 
elevated fasting glucose. 6  Table 1 provides the modified categorical cut-off points for the 
five Metabolic Syndrome diagnostic criteria with the modifications including medical 
treatment received for diabetes, hypertension or elevated triglycerides. 2   
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Three of the five symptoms must pass the threshold criterion in order for a Metabolic 
Syndrome diagnosis to be established. 2  A diagnosis of Metabolic Syndrome comes with an 
increased risk for cardiovascular disease and type II diabetes mellitus. 7  While a diagnosis 
of Metabolic Syndrome increases risk of diabetes, once diabetes is present the subsequent 
risk for cardiovascular disease is increased even further. 7  Metabolic Syndrome with the 
presentation of insulin resistance is further associated with fatty liver, polycystic ovary 
syndrome, cholesterol gallstones, sleep apnea and lipodystrophies. 7  Metabolic Syndrome 
is becoming more common in society due to the increase in obesity rate; a Korean National 
Health and Nutrition Examination Survey found the prevalence of Metabolic Syndrome 
worldwide rose from 19.6% in 1998 to 32.4% in 2009. 4,7  In addition to the increased 
prevalence of cardiovascular disease, diabetes and the plethora of other health problems 
stemming from Metabolic Syndrome comes an influx in hospital visits and overall health 
care costs.  Cardiovascular disease is the leading cause of death in the United States; in 
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2011, 596,577 people died from cardiovascular diseases costing the US $273 billion dollars 
in 2010. 8,9  This accounts for some 17% of national health expenditures and these costs are 
expected to significantly increase to roughly $818 billion dollars in 2030. 8  While diabetes 
itself increases risk for health problems such as cardiovascular disease and stroke it is the 
leading cause of kidney failure, non-traumatic lower limb amputations and new cases of 
blindness in the US. 10  Diabetes was the seventh leading cause of death in the US in 2011; it 
directly killed 73,831 people and an additional 160,022 people had diabetes listed as a 
contributing factor to their deaths in 2007. 9,10  Diabetes cost the US $174 billion dollars in 
total in 2007. 10  These figures and statistics indicate the significance a diagnosis of 
Metabolic Syndrome has and the importance of continued Metabolic Syndrome research. 
Cushing’s Syndrome is a disorder with a broad clinical presentation that is 
characterized and diagnosed by hypercortisolism. 11  Cushing’s can either be primary ( 
Cushing’s Syndrome) or secondary (Cushing’s Disease).  In the primary form the disorder is 
due to a defect at the site of cortisol production and is independent of the hormone 
stimulating cortisol’s release. 3  The secondary form is dependent upon the hormone 
signaling cortisol’s release and is a result of a defect not at the site of cortisol production.  3  
As both result in hypercortisolemia, they will be referred to collectively as Cushing’s 
Syndrome.  Cushing’s Syndrome’s distinctive features include reddish or purple striae, 
facial plethora and rounding, dorsocervical fat pads, centripetal, or abdominal, obesity and 
proximal muscle weakness.  11,12  Many studies have acknowledged the phenotypic 
similarities between Cushing’s Syndrome and Metabolic Syndrome. 2-4,12,13  Such 
similarities can be viewed in Figure 1. 
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Since the two syndromes have so many similarities, it has been hypothesized, by our lab 
and others, that in some cases Metabolic Syndrome represents a Cushing’s Syndrome like 
state in the absence of elevated cortisol levels. 2  One potential mechanism by a Cushing’s 
Syndrome like state could occur without elevated cortisol levels is if the glucocorticoid 
receptor has an elevated sensitivity to glucocorticoids as a result of one or more mutations 
to the glucocorticoid receptor. 
Cortisol is a steroid hormone, more specifically a glucocorticoid, which is produced 
in response to stress.  14  Its production is part of the hypothalamic-pituitary-adrenal (HPA) 
axis. 14  The HPA axis is seen in Figure 2. 15   
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The hypothalamus in the brain responds to a stressor, either chronic or acute, by releasing 
corticotropin-releasing hormone (CRH). 16  CRH travels to the anterior pituitary gland 
where it stimulates the release of adrenocorticotropic hormone (ACTH), which 
subsequently travels to the adrenal cortex of the adrenal gland, specifically the middle 
layer of the cortex, the zona fasciculata, and promotes the release of cortisol. 16  Cortisol 
release is regulated by long-loop negative feedback whereby cortisol inhibits both the 
hypothalamus’s release of CRH and the anterior pituitary’s release of ACTH.  16  Cortisol’s 
target is the glucocorticoid receptor and due to varying receptor sensitivities among 
individuals, the effects of glucocorticoids themselves vary greatly. 3  Cortisol’s role, in 
addition to its immunosuppressant effects, is to increase blood glucose levels, central fat, 
bone resorption and arterial tone while decreasing muscle mass and bone formation.  3,4,14  
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More broadly, it is responsible for insulin resistance, diabetes, dyslipidemia and 
cardiovascular disease, many of the diagnostic criteria for Metabolic Syndrome. 3   Evidence 
suggests a causal relationship between cortisol and obesity, specifically the abdominal 
obesity that is characteristic of both Metabolic Syndrome and Cushing’s Syndrome. 2,3  
Cortisol is the link that binds together Metabolic Syndrome and Cushing’s Syndrome.  In 
addition to abdominal obesity, chronic exposure to excess cortisol is responsible for the 
clinical phenotype of Cushing’s Syndrome.  3    
The glucocorticoid receptor is an intracellular steroid hormone receptor coded for 
by the gene NR3C1 located on chromosome five. 17  When not bound to cortisol, the 
glucocorticoid receptor is located in the cytoplasm of the target cell along with multiple 
heat shock proteins. 18  Once cortisol diffuses through the cell membrane and binds the 
receptor, the receptor homodimerizes and receptor and ligand translocate to the nucleus of 
the cell where it regulates gene transcription.  18  The bound receptor can either activate or 
repress gene expression, known as transactivation and transrepression, respectively, by 
interacting with glucocorticoid response elements within the promoter regions of the 
target genes.  18  The varying glucocorticoid receptor sensitivities among individuals are 
determined mostly empirically and several polymorphisms of the glucocorticoid receptor 
gene that alter glucocorticoid sensitivity have been identified as summarized in Figure 3. 
3,14,19   
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Two particular polymorphisms of the glucocorticoid receptor that positively correlate with 
hypersensitivity to cortisol, the asparagine to serine mutation at the 363rd codon of the 
receptor gene (N363S) as well as a mutation that abolishes the BclI site on the second 
intron of the receptor gene, positively correlate with characteristics of Metabolic 
Syndrome.20  
The N363S mutation is a single nucleotide polymorphism (SNP) located at the 
1220th nucleotide mutating an adenine to a guanine (AAT to AGT), thus making the 363rd 
codon serine as opposed to the wild type asparagine. 17,18  This mutation is associated with 
increased sensitivity to glucocorticoids in vivo as well as increased body mass index (BMI). 
17,18,21,22  Further, the N363S mutation is associated with a tendency toward higher insulin 
resistance, increased blood pressure and decreased HDL-C levels. 17,18,22  One study 
reported the presence of the heterozygous N363S polymorphism in between 1.2 and 6.8% 
of a Caucasian population tested while another study found between 3.9 and 9.3% of a 
Caucasian population of European descent heterozygous for the mutation. 17,22  Australian 
individuals have among the highest prevalence of the polymorphism with studies reporting 
between 9.4 to 19.8% heterozygous for the mutation. 17,23  Allelic frequency of the N363S 
mutant allele has been reported to be around 6%.15  It is clear that the prevalence of the 
polymorphism varies by ethnicity as two additional studies found the mutation was not 
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detected in a population of 192 Japanese individuals and an extremely low prevalence 
among a population of South Asian individuals. 17,23  All reported individuals with 
mutations were heterozygous; no homozygotes for the mutation were observed in any of 
three European populations.23  
The mutation at the BclI site of the glucocorticoid receptor gene is also correlated 
with increased sensitivity to cortisol as well as abdominal obesity and insulin resistance. 18-
20  The mutation is the loss of the BclI restriction site in the second intron of the 
glucocorticoid receptor gene 646 base pairs from the exon 2/intron 2 junction. 19  The 
mutation is a SNP transitioning a cytosine to a guanine. 18-20,23  One study has indicated a 
27% allelic frequency of the G allele in their obese patients and another study found 9.7% 
of their population to be homozygous for the mutation with an additional 41.7% of their 
population heterozygous for the mutation. 20,23  One study noted that the BclI 
polymorphism occurs more frequently in a Caucasian population than in other ethnic 
groups. 20  Allelic frequency of the Bcl1 mutant allele has been reported to be around 35%. 
15 Our lab hypothesizes that in a population of non-obese college students with normal 
range BMIs there will be a lower frequency of the mutant alleles for both the N363 as well 











 The study enrolled 8 undergraduate students, mostly white, with normal range 
BMIs.  The mean BMI was 23.5 kg/m2 with the standard deviation of the mean was 
calculated to be 4.7. 
 
DNA Isolation 
The experimental approach utilized in this investigation began with collecting cheek 
cells from the enrolled subjects.  The cheek cells were obtained by a buccal wash; a saline 
solution was swished inside the subjects’ mouths and returned to individual collection 
tubes.  DNA extraction and isolation was then performed using a 10% CHELEX solution in 
50mM Tris at 9.5pH.  The cheek cells were pelleted in the collection tubes, the CHELEX 
solution was then added, the mixture vortexed, heated, cooled and again pelleted to 
retrieve the supernatant containing the subject’s DNA. 
 
Allele Specific Primers and DNA Amplification 
 Amplification of the DNA to identify the presence or absence of the N363S and BclI 
polymorphisms utilized an allele-specific polymerase chain reaction (PCR).  That is, the 
artificial primers designed to anneal to the template strands and begin extension were 
designed to only anneal in the presence of either the wild type allele when reacting the 
template with the wild type allele-specific primer or the mutant allele when reacting the 
template with the mutant allele-specific primer.  This specificity is seen in Figure 4. 
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Figure 4. Allele-Specific Primer Polymerase Chain Reaction Diagram 
Wild type, mutant and common primer location indicated using 5’  3’ arrows.  Template 
displays wild type sequence.  Primers include mismatch at penultimate nucleotide. 
 
The Bcl1 and N363S sites in Figure 3 include the penultimate and ultimate nucleotides 
present in the wild type sequence, therefore the indicated mutant primers will not anneal.  
To increase specificity of the reaction further, mismatched nucleotides at the penultimate 
positions of the allele-specific primers were introduced.  The primer sequences are found 
in Table 2. 
 
Table 2. Bcl1 and N363S PCR Primers 
Name Sequence (5’  3’) 
N363S.2/4Forward CCAGTAATGTAACACTGCCCC 
N363S WT AGATCCTTGGCACCTATTCCATT 
N363S MUT AGATCCTTGGCACCTATTCCATC 
BclI WT AGTAGACAAGTTATGTCTGCTGACC 
BclI MUT AGTAGACAAGTTATGTCTGCTGACG 
BclI Downstream  AAATCAAACGAAAGCTGAAA 
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Using the specifically designed primers, PCR was used to amplify the target sequence.  Each 
PCR reaction was 50μl total volume and contained water, 10x NovaTaq buffer with 15mM 
MgCl2+, 10mM each dNTPs mix, TAq polymerase, common primer and one allele-specific 
primer.  All PCR protocols include an initial 95°C denaturation step followed by 35 cycles of 
a 95°C denaturation, an annealing step, a 72°C extension.  Both protocols included a final 
72°C elongation step.  The annealing temperature for the BclI reaction was optimized to 
52°C while the annealing temperature for the N363S reaction was optimized to 56°C.  PCR 
products were separated on a 2% agarose gel using electrophoresis and imaged using an 




 Through countless rounds of reaction optimization, the allele-specific primers 
properly annealed and showed specificity for the presence or absence of the BclI 
polymorphism for all 8 subjects’ samples. The BclI results can be seen in Figure 5. 
 
Figure 5. Detection of the BclI Polymorphism by Agarose Gel Electrophoresis 
Genomic DNA was reacted with allele-specific primers (WT or MT) in a polymerase chain 
reaction for 35 cycles with the annealing temperature optimized to 52°C.  Detection of 
genomic bands was conducted using 2% agarose gel electrophoresis, ethidium bromide 
staining and UV imaging. 
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Using the 100 base pair ladder in the leftmost lane as reference, the products can be seen to 
be 159 base pairs.  The gel image indicates 3 homozygote wild type subjects, 1 homozygote 
mutant subject and 4 heterozygote subjects.  This results in a 21% BclI mutant allele 
frequency within our sample. 
For the detection of the N363S polymorphism, the reaction was only successful for 5 
of the 8 subjects’ samples.  For the remaining 3 subjects’ samples, no bands were detected 
using the standard imaging method utilized for the BclI reaction.  The N363S results can be 
seen in Figure 6.  
 
Figure 6. Detection of the N363S Polymorphism by Agarose Gel Electrophoresis 
Genomic DNA was reacted with allele-specific primers (WT or MT) in a polymerase chain 
reaction for 35 cycles with the annealing temperature optimized to 56°C.  Detection of 
genomic bands was conducted using 2% agarose gel electrophoresis, ethidium bromide 
staining and UV imaging. 
 
Using the brightest band in the ladder as a 500 base pair reference, these bands 
corresponding to the amplified products can be seen to be 306 base pairs.  The gel image 
indicates all 5 subjects’ samples that successfully reacted to be homozygote wild type.  The 





 The results for the BclI mutation of 3 homozygous wild type subjects, 1 homozygous 
mutant subject and 4 heterozygous subjects as well as the results for the N363S mutation 
of 5 homozygous wild type subjects supports the lab’s hypothesis that in a population of 
non-obese college students with normal range BMIs there will be a lower frequency of the 
mutant alleles for both the N363 as well as the BclI polymorphisms as compared to the 
general population.  One study indicated that the mutant allele frequency for the N363S 
polymorphism is roughly 6% whereas the mutant allele frequency for the BclI 
polymorphism is roughly 35%.  Our results of 0% and 21% mutant allele frequency for the 
N363S and BclI polymorphisms, respectively, therefore support the hypothesis.15  
 Throughout the optimization process, the N363S detection reaction presented as 
troublesome.  This is further indicated by the dropout of 3 of the 8 samples reacted with 
N363S allele specific primers.  These dropouts could be caused by any a number of reasons 
including, but not limited to, deterioration of the 3 genetic samples, an insufficient 
concentration of the genetic samples, an exceedingly high concentration of the genetic 
samples or simply an increased sensitivity of the template to the annealing temperature.  
The BclI reaction was successful in displaying specificity for all samples tested after the 
lengthy optimization process. 
 Both the BclI and N363S polymorphisms increase sensitivity to glucocorticoids, 
however the N363S polymorphism is located within an exon while the BclI polymorphism 
is found in an intron.  As introns are noncoding sequences, it is not intuitive that a mutation 
here could effect subsequent transcription.  The BclI polymorphism is only located 646 
base pairs away from the intron/exon junction and therefore its likely disruptional effect is 
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on splicing.   Another likely mechanism by which the BclI polymorphism could alter 
sensitivity is it being linked with other polymorphisms in more critical regions such as the 
promoter region or elsewhere. The polymorphism could introduce an insertion or a 
skipping effect to eliminate an adjacent exon from the RNA transcript.  This could certainly 
affect responsiveness to glucocorticoids.   
 This study successfully validated that glucocorticoid receptor polymorphisms can 
be detected by allele specific PCR rapidly and inexpensively.  This study was limited by its 
small sample size.  Future research will focus on a much larger sample size and incorporate 
many other pieces of data to be analyzed along with the genetic screen.  Already underway 
is collaboration with our lab at Union College and Ellis Hospital’s Bariatric Surgery Group.  
Our lab hypothesizes that a population of patients presenting with Metabolic Syndrome 
will have an increased frequency of one or more of the hypersensitivity-causing 
polymorphisms than the patients without.  Further, we intend to investigate the presence 
of a synergistic effect on the patients’ phenotypes due to the presence of both N363S and 
Bcl1 polymorphisms.  Further, our lab hypothesizes that the presence of glucocorticoid 
hypersensitivity will represent a predictive indicator for success after bariatric surgery as 
measured by rate of weight loss and ability of a patient to maintain weight loss.  If 
glucocorticoid hypersensitivity correlates with failure to maintain weight loss, this could 
represent a novel avenue for understanding and ultimately treating these patients without 
performing revisional surgery.  The implications of this investigation are great as genetic 
screening is becoming more popular as the technology to analyze Big Data improves.  Such 
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